IOM Proposals for Overhaul at CIRM Win High Marks
By David Jensen,
California Stem Cell Report
| 12. 07. 2012
[Quotes CGS's Marcy Darnovsky]
The Institute of Medicine's recommendations for major changes at the California stem cell agency today received generally high marks from independent observers and critics.
Many of the proposals echoed suggestions from California's Little Hoover Commission, the state's good government agency. Asked for comment, Stuart Drown, the commission's executive director, said,
“The institute’s recommendations for much-needed changes to CIRM’s governance structure to provide greater efficiency, clarity and accountability reinforce the recommendations the Little Hoover Commission made in 2009."
He continued,
“Then and now, the Commission’s recommendations are aimed at improving
CIRM’s ability to meet its goals for the good of all who can benefit
from stem cell research, and to ensure that California taxpayers’
dollars are put to their most efficient use to that end.”
The California Stem Cell Report also asked the agency's first president,
Zach Hall, for his thoughts. Here is the full text of what Hall, who
was one of the peer reviewers on the IOM study, had to say,
“The IOM Committee and its staff have done an impressive job. The
report recognizes the scientific value and...
Related Articles
By Rhys Blakely, The Times | 06.24.2025
Scientists have created fertile mice from male genetic material alone, a breakthrough that could one day open the door to human babies who inherit their genes from two fathers.
The experiment, led by Professor Yanchang Wei at Shanghai Jiao Tong...
By Ron Leuty, San Francisco Business Times | 06.16.2025
23andMe's two-step sale to a nonprofit led by former CEO Anne Wojcicki is nothing more than a dance around California's genetic privacy law, state Attorney General Rob Bonta said in a filing late Monday, one day before a judge will...
By Angus Liu, Fierce Pharma | 06.16.2025
A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile.
Sarepta and its ex-U.S. partner Roche reported the death early Sunday. Like the first case, disclosed...
By Gina Kolata, The New York Times | 06.20.2025
A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of type 1 diabetes. One year later, these 10 patients no longer need insulin. The other two patients need...